Search results for "reports"

showing 10 items of 221 documents

IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus …

2012

Background. Polymorphisms in the interleukin-28B are important determinants in the spontaneous and drug-induced control of hepatitis C virus infection. Design and Methods. We assessed the association of rs8099917 and rs12979860 polymorphisms with spontaneous viral clearance, severity of liver fibrosis, and response to interferon-monotherapy in 245 Thalassemia Major patients with Hepatitis C Virus infection. Results. Ninety-eight patients (40%) had a spontaneous viral clearance, while 147 patients (60%) developed a chronic infection. Spontaneous viral clearance was more frequent among patients with the T/T genotype of rs8099917 polymorphism (OR 2.130; p=0.008) or C/C genotype of rs12979860 p…

AdultLiver CirrhosisMalethlassemia hepatitis CInterferon InducersAdolescentHepacivirusHepatitis C virusAlpha interferonHepacivirusAdolescent; Adult; Antibodies Viral; Antiviral Agents; Cohort Studies; Female; Follow-Up Studies; Hepacivirus; Hepatitis C Chronic; Humans; Interferon Inducers; Interferon-alpha; Interleukins; Liver Cirrhosis; Male; Polymorphism Single Nucleotide; Prognosis; Viral Load; Young Adult; beta-Thalassemiamedicine.disease_causeAntibodies ViralAntiviral AgentsPolymorphism Single NucleotideCohort StudiesYoung AdultGenotypemedicineHumansInterferon inducerbiologymedicine.diagnostic_testInterleukinsbeta-ThalassemiaInterferon-alphaHematologyHepatitis CHepatitis C ChronicViral Loadbiology.organism_classificationmedicine.diseasePrognosisLiver biopsyImmunologyFemaleInterferonsOriginal Articles and Brief ReportsViral loadFollow-Up Studies
researchProduct

The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammatio…

2013

Macrophages reside in tissues infiltrated by chronic lymphocytic leukemia B cells and the extent of infiltration is associated with adverse prognostic factors. We studied blood monocyte population by flow cytometry and whole-genome microarrays. A mixed lymphocyte reaction was performed to evaluate proliferation of T cells in contact with monocytes from patients and normal donors. Migration and gene modulation in normal monocytes cultured with CLL cells were also evaluated. The absolute number of monocytes increased in chronic lymphocytic leukemia patients compared to the number in normal controls (792 +/- 86 cells/mu L versus 485 +/- 46 cells/mL, P=0.003). Higher numbers of non-classical CD…

AdultMaleCD14Chronic lymphocytic leukemiaPhagocytosisPopulationDown-RegulationInflammationMICROENVIRONMENTCD16BiologyTUMOR-ASSOCIATED MACROPHAGES; TIE2-EXPRESSING MONOCYTES; MICROENVIRONMENT; CLLMonocytesImmune systemPhagocytosismedicineHumanseducationCells CulturedAgedAged 80 and overInflammationeducation.field_of_studyMonocyteGene Expression ProfilingHematologyMiddle Agedmedicine.diseaseLeukemia Lymphocytic Chronic B-CellTIE2-EXPRESSING MONOCYTESGene Expression Regulation NeoplasticChronic Lymphocytic Leukemia; Monocyte; microenvironmentTUMOR-ASSOCIATED MACROPHAGESmedicine.anatomical_structureImmunologyFemalemedicine.symptomLymphocyte Culture Test MixedOriginal Articles and Brief ReportsCLLHaematologica
researchProduct

Hematopoietic stem-cell transplantation for advanced systemic mastocytosis

2014

Purpose Advanced systemic mastocytosis (SM), a fatal hematopoietic malignancy characterized by drug resistance, has no standard therapy. The effectiveness of allogeneic hematopoietic stem-cell transplantation (alloHCT) in SM remains unknown. Patients and Methods In a global effort to define the value of HCT in SM, 57 patients with the following subtypes of SM were evaluated: SM associated with clonal hematologic non–mast cell disorders (SM-AHNMD; n = 38), mast cell leukemia (MCL; n = 12), and aggressive SM (ASM; n = 7). Median age of patients was 46 years (range, 11 to 67 years). Donors were HLA-identical (n = 34), unrelated (n = 17), umbilical cord blood (n = 2), HLA-haploidentical (n = 1)…

AdultMaleCancer Researchmedicine.medical_specialtyTransplantation ConditioningAdolescentmedicine.medical_treatmentMedizinDrug resistanceHematopoietic stem cell transplantationMastocytosis SystemicInternal medicinemedicineHumansTransplantation HomologousSystemic mastocytosisChildSurvival rateAgedRetrospective StudiesmastocytosisHematologybusiness.industryRemission InductionHematopoietic Stem Cell TransplantationORIGINAL REPORTSMiddle Agedmedicine.diseaseMast cell leukemia3. Good healthSurvival RateTransplantationSettore MED/15 - MALATTIE DEL SANGUEHaematopoiesisTreatment OutcomeOncologyImmunologyCancer researchFemalebusinesstransplantation
researchProduct

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera

2021

Vaccine protects against B1.1.7 variant The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B1.1.7 (VOC 202012/01) variant that emerged in late 2020 in the United Kingdom has many changes in the spike protein gene. Three of these are associated with enhanced infectivity and transmissibility, and there are concerns that B.1.1.7 might compromise the effectiveness of the vaccine. Muik et al. compared the neutralization efficacy of sera from 40 subjects immunized with the BioNTech-Pfizer mRNA vaccine BNT162b2 against a pseudovirus bearing the Wuhan reference strain or the lineage B.1.1.7 spike protein (see the Perspective by Altmann et al.). Serum was derived from 40 subjects in tw…

AdultMaleChinaCOVID-19 VaccinesLineage (genetic)Coronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Antibodies ViralNeutralizationYoung AdultNeutralization TestsReportHumansBNT162 VaccineAgedchemistry.chemical_classificationVaccinesMessenger RNAMultidisciplinarybiologySARS-CoV-2COVID-19MicrobioMiddle AgedAntibodies NeutralizingVirologyUnited KingdomAmino acidTiterchemistrySpike Glycoprotein Coronavirusbiology.proteinMedicineFemaleAntibodyReportsScience
researchProduct

Transpalpebral tonometry: reliability and comparison with Goldmann applanation tonometry and palpation in healthy volunteers

2005

Background/aim: TGDc-01 is a new, portable, transpalpebral tonometry device. The aim of this study was to evaluate the reproducibility of this method, including intraobserver and interobserver deviations, and to compare the results with those of Goldmann applanation tonometry and palpation of intraocular pressure (IOP). Methods: A total of 40 eyes of 20 healthy volunteers were included. Two independent parallel observers (1 and 2) performed three replicate measurements per eye, respectively, both using TGDc01 tonometry, one observer (3) performed three replicate measurements using Goldmann applanation tonometry, and one observer (4) measured the IOP via palpation. Intraindividual deviations…

AdultMaleIntraocular pressuremedicine.medical_specialtyClinical Science - Scientific ReportsPalpationGoldmann applanation tonometryTonometry OcularCellular and Molecular NeuroscienceInterquartile rangeOphthalmologyHealthy volunteersHumansMedicineIn patientIntraocular PressureObserver VariationReproducibilityPalpationmedicine.diagnostic_testbusiness.industryReproducibility of ResultsEquipment DesignSensory SystemsOphthalmologyQuartileFemalebusinessBritish Journal of Ophthalmology
researchProduct

Maintenance treatment for opioid dependence with slow‐release oral morphine: a randomized cross‐over, non‐inferiority study versus methadone

2012

Aims To compare the efficacy of slow-release oral morphine (SROM) and methadone as maintenance medication for opioid dependence in patients previously treated with methadone. Design Prospective, multiple-dose, open label, randomized, non-inferiority, cross-over study over two 11-week periods. Methadone treatment was switched to SROM with flexible dosing and vice versa according to period and sequence of treatment. Setting Fourteen out-patient addiction treatment centres in Switzerland and Germany. Participants Adults with opioid dependence in methadone maintenance programmes (dose ≥50 mg/day) for ≥26 weeks. Measurements The efficacy end-point was the proportion of heroin-positive urine samp…

AdultMaleNarcoticsMethadone maintenanceretention ratePopulationslow-release oral morphineAdministration OralMedicine (miscellaneous)Maintenance ChemotherapyMedication AdherencemethadoneOpiate Substitution TreatmentmedicineHumanseducationMorphine Derivativeseducation.field_of_studyCross-Over StudiesMorphinemaintenance treatmentCodeinebusiness.industryCodeineResearch ReportsOpioid use disorderOpiate Substitution TreatmentMiddle AgedOpioid-Related Disordersmedicine.diseaseCrossover studyPsychiatry and Mental healthTreatment OutcomeOpioidDelayed-Action PreparationsAnesthesiaFemaleDose–responsebusinessopioid addictionMethadonemedicine.drugAddiction
researchProduct

Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study

2015

Purpose Peripheral T-cell lymphomas (PTCLs) represent a diverse group of non-Hodgkin lymphomas with a poor prognosis and no accepted standard of care for patients with relapsed or refractory disease. This study evaluated the efficacy and tolerability of belinostat, a novel histone deacetylase inhibitor, as a single agent in relapsed or refractory PTCL. Patients and Methods Patients with confirmed PTCL who experienced progression after ≥ one prior therapy received belinostat 1,000 mg/m2 as daily 30-minute infusions on days 1 to 5 every 21 days. Central assessment of response used International Working Group criteria. Primary end point was overall response rate. Secondary end points included …

AdultMaleOncologyCancer Researchmedicine.medical_specialtymedicine.drug_classAntineoplastic AgentsKaplan-Meier EstimateHydroxamic AcidsDisease-Free SurvivalDrug Administration Schedulechemistry.chemical_compoundRefractoryInternal medicineClinical endpointHumansMedicineInfusions IntravenousAgedAged 80 and overSulfonamidesbusiness.industryHistone deacetylase inhibitorLymphoma T-Cell PeripheralORIGINAL REPORTSMiddle Agedmedicine.diseaseLymphomaSurgeryHistone Deacetylase InhibitorsClinical trialTreatment OutcomePrior TherapyOncologyTolerabilitychemistryDrug Resistance NeoplasmFemaleNeoplasm Recurrence LocalbusinessBelinostatJournal of Clinical Oncology
researchProduct

Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation

2013

High-dose chemotherapy followed by autologous stem cell transplantation has been shown to be feasible and highly effective in newly diagnosed primary central nervous system lymphoma. In this retrospective multicenter study, we investigated prognosis and baseline risk factors in patients with primary central nervous system lymphoma who underwent this treatment approach. We retrospectively analyzed 105 immunocompetent patients with primary central nervous system lymphoma who underwent high-dose chemotherapy followed by autologous stem cell transplantation with or without whole brain radiotherapy as first-line consolidation treated at 12 German centers between 1997 and 2011. We estimated survi…

AdultMaleOncologymedicine.medical_specialtyLymphomamedicine.medical_treatmentAntineoplastic AgentsHematopoietic stem cell transplantationTransplantation AutologousCentral Nervous System NeoplasmsYoung AdultAutologous stem-cell transplantationRisk FactorsMedian follow-upInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineAgedRetrospective StudiesChemotherapyRadiotherapyPerformance statusbusiness.industryHematopoietic Stem Cell TransplantationPrimary central nervous system lymphomaHematologyMiddle AgedPrognosismedicine.diseaseCombined Modality TherapySurgeryTransplantationRadiation therapyTreatment OutcomeFemaleOriginal Articles and Brief ReportsbusinessHaematologica
researchProduct

Ankylosing spondylitis in monozygotic twins: studies on immunological parameters

1999

OBJECTIVE—To examine immunological parameters that might explain disease discordance in monozygotic twin pairs with ankylosing spondylitis (AS). METHODS—11 monozygotic twin pairs (nine with AS, two with undifferentiated spondyloarthropathy) were investigated. The peripheral T cell receptor Vβ repertoire was investigated using FACS analysis and 14 different Vβ antibodies. In addition serum samples were tested for antibodies to Klebsiella pneumoniae, Streptococcus pyogenes, Candida albicans, Proteus mirabilis, and Escherichia coli. Peripheral blood lymphocyte reactivity against a number of bacteria was investigated by interferon γ ELISPOT assays. RESULTS—Twins suffering from AS showed cellula…

AdultMaleReceptors Antigen T-Cell alpha-betaT cellImmunologyMonozygotic twinEnzyme-Linked Immunosorbent AssayBiologyStatistics NonparametricGeneral Biochemistry Genetics and Molecular BiologyExtended ReportsMicrobiologyRheumatologyAntigenKlebsiellaDiseases in TwinsmedicineHumansImmunology and AllergySpondylitis AnkylosingAgedChi-Square DistributionELISPOTTwins MonozygoticMiddle AgedFlow CytometryAntibodies Bacterialmedicine.anatomical_structurePeripheral blood lymphocyteImmunologybiology.proteinFemaleBacterial antigenAntibodyCD8Annals of the Rheumatic Diseases
researchProduct

CD146+ bone marrow osteoprogenitors increase in the advanced stages of primary myelofibrosis

2008

Abstract CD146+ bone marrow stromal cells have been recently recognized as clonogenic osteoprogenitors able to organize a complete hematopoietic microenvironment. In this study we used immunohistochemical analysis to investigate the contribution of CD146+ bone marrow osteoprogenitors to the stromal remodeling occurring in the different stages of primary myelofibrosis. We found that CD146+ cells sited at the abluminal side of the bone marrow vessels and branching among hematopoietic cells significantly increased in the advanced stages of primary myelofibrosis (p<0.001), paralleling the extent of fibrosis (r=0.916, p<0.0001) and the microvascular density (r=0.883, p<0.0001). Coherently with a…

AdultMalebone marrow stromal cellmedicine.medical_specialtyPathologyStromal cellAngiogenesisBone Marrow CellsCD146 AntigenBiologyMural cellInternal medicinemedicineHumansMyelofibrosisAgedCell ProliferationNeoplasm StagingAged 80 and overHematologyCD146; bone marrow stromal cells; primary myelofibrosisStem CellsHematologyMiddle Agedmedicine.diseaseHaematopoiesismedicine.anatomical_structureCD146Primary MyelofibrosisBrief ReportsFemaleBone marrowStem cell
researchProduct